Home › Funds › BRAIDWELL LP › RYTM
BRAIDWELL LP position in RYTM
RHYTHM PHARMACEUTICALS INC · Health Care
BRAIDWELL LP reported holding 381,128 shares of RYTM (RHYTHM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$42.3M, representing 1.67% of its reported portfolio and ranking #19 among its reported holdings. BRAIDWELL LP has disclosed RYTM holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BRAIDWELL LP's RYTM position evolved
BRAIDWELL LP first disclosed a stake in RYTM in Q1 2026 at 310,628 shares (US$27.0M). The position peaked in Q2 2026 at 381,128 shares, worth US$42.3M. Across 2 filings, BRAIDWELL LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 381,128 shares valued at US$42.3M — an increase of 70,500 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 310.63K | $27.02M | New |
| Q2 2026 | 381.13K | $42.32M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RYTM and 13F data
RYTM (RHYTHM PHARMACEUTICALS INC) is a Health Care company. 51 other funds we track also report a position in RYTM — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$740.2M), BAKER BROS. ADVISORS LP (US$622.3M), PERCEPTIVE ADVISORS LLC (US$287.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RYTM
- RA CAPITAL MANAGEMENT, L.P. 6.67M sh · $740.22M · Q2 2026
- BAKER BROS. ADVISORS LP 5.60M sh · $622.27M · Q2 2026
- PERCEPTIVE ADVISORS LLC 2.59M sh · $287.16M · Q2 2026
- WESTFIELD CAPITAL MANAGEMENT CO LP 2.21M sh · $245.22M · Q2 2026
- Polar Capital Holdings Plc 1.66M sh · $184.71M · Q2 2026
- Checkpoint Capital L.P. 1.19M sh · $131.68M · Q2 2026
- Siren, L.L.C. 1.14M sh · $126.16M · Q2 2026
- Rock Springs Capital Management LP 692.60K sh · $76.90M · Q2 2026
- Integral Health Asset Management, LLC 550.00K sh · $61.07M · Q2 2026
- Sofinnova Investments, Inc. 408.03K sh · $45.30M · Q2 2026
FAQ
How long has BRAIDWELL LP held RYTM?
BRAIDWELL LP has disclosed RYTM holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is BRAIDWELL LP's current position in RYTM?
As of Q2 2026, BRAIDWELL LP holds 381.13K shares of RYTM (RHYTHM PHARMACEUTICALS INC), valued at $42.32M, representing 1.67% of its reported portfolio and ranking #19.
Has BRAIDWELL LP been buying or selling RYTM?
In the latest 13F filing (Q2 2026), BRAIDWELL LP increased its position in RYTM. The position peaked in Q2 2026 at 381.13K shares.
Which other funds hold RYTM?
Other major institutional holders of RYTM include RA CAPITAL MANAGEMENT, L.P., BAKER BROS. ADVISORS LP, PERCEPTIVE ADVISORS LLC, among 51 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.